Drug Resistance 2: Tyrosine Kinase Inhibitors

• 7022 7022 Investigating PRMT5 as a therapeutic target in EGFR TKI resistant NSCLC and assessing the role of mucins in NSCLC as blood biomarkers Aditya Krishnan, James Jin, Usama Altayeh, Jessica Hindenburg, Neelu Puri
• 7024 · PDF Simultaneous targeting of CHI3L1 and PD-1/PD-L1 axis to overcome drug resistance and immune tolerance of EGFR non-small cell lung cancer Suchitra Kamle, Bing Ma, Brianna Pham, Isabella Fish, Marlo Hulnick, Taka Sadanaga, Hanseok Jeong, Mara Hofstetter, Hina Khan, Christopher Azzoli, Katerina A. Politi, Roy S. Herbst, Chun Geun Lee, Jack Elias
• 7025 · PDF Mechanisms of zongertinib resistance in HER2-mutant non-small cell lung cancer and potential strategies to overcome resistance Yuji Shibata, Monique B. Nilsson, Ximeng Liu, Li (Lily) Cai, Hong Jiang, Linghzi Hong, Alvaro Guimaraes Paula, Hibiki Udagawa, Jacqulyne Ponville Robichaux, Junqin He, Xiaoxing Yu, John V. Heymach
• 7026 · PDF IL-1 alpha expression induces drug resistance to all generations of EGFR inhibitors in HNSCC Nafis Md Irfan, Ishrat Nourin Khan, Nurgul Koyuncu, Krishna Awasthi, Andrean L. Simons-Burnett
• 7027 · PDF Multi-lineage evolution of drug resistance via a novel keratin 17+ drug tolerant persister population in EGFR -mutant NSCLC Benjamin B. Morris, Monique B. Nilsson, Ethan Earlie, Eric E. Gardner, Hong Chen, Santiago G. Trevino, Alexa J. Halliday, Yuanxin Xi, Jing Wang, Natalie Vokes, Don Gibbons, Jianjun Zhang, Ashley M. Laughney, Yasir Y. Elamin, Xiuning Le, John V. Heymach
• 7028 · PDF Investigating the role of PLK4 and GDF15 in NSCLC tumorigenicity and EGFR-TKI resistance Subaranjana Saravanaguru Vasanthi, Georgia Kapetaneas, Meet Patel, Neelu Puri
• 7029 · PDF Engineering isogenic models harboring resistance mechanisms to the latest-generation EGFR inhibitor in non-small cell lung cancer Hyeyoun Chang, Florencia M. Rowdo, Kirsty Wienand, John G. Foulke, Paul Lovell, Francisca Vasquez, Fang Tian
• 7030 · PDF Tumor-macrophage crosstalk promotes resistance to EGFR targeted therapy in lung adenocarcinoma Philippe Gui, Victor Olivas, Tiffany Li, Whitney Tamaki, Hannah Bergo, D. Lucas Kerr, Wei Wu, Collin M. Blakely, Trever G. Bivona
• 7031 · PDF Intra-tumoral Porphyromonas gingivalis mediates osimertinib resistance in EGFR-mutant lung adenocarcinoma through gingipain-mediated IGF1R activation Wendong Li, Mahima Raul, Keqiang Zhang, Jan Potempa, Yuanyuan Gao, Dan Raz
• 7032 · PDF GLAST (SLC1A3), a novel therapeutic target for overcoming osimertinib resistance in lung cancer Sara Bernstein, Sophie Kim, Clara Takanohashi, Beatriz P. Peixoto, Kathy Nguyen, Hiromi Inoue Wettersten
• 7033 · PDF Inhibition of PGC1b/mitochondrial biogenesis as a critical event in mediating therapeutic response of EGFR mutant NSCLC to third generation EGFR inhibitors Zhen Chen, Dongsheng Wang, Songqing Fan, Qiming Wang, Suresh S. Ramalingam, Shi-Yong Sun
• 7034 · PDF The potential of dequalinium chloride and osimertinib combination in overcoming osimertinib acquired resistance in EGFR-mutant non-small cell lung cancer Jing Sun, Dongsheng Wang, Suresh S. Ramalingam, Zhen Chen, Shi-Yong Sun
• 7035 · PDF CD24 as a therapeutic vulnerability in osimertinib-induced drug-tolerant persister cells of EGFR-mutant NSCLC Ji Ae Ko, Ji Hyung Moon, Youwon Lee, Minyeop Kim, Eun Ji Lee, Seung Yeon Oh, JI WOO LIM, So Young Park, Sujin Choi, Jii Bum Lee, Min Hee Hong, Jae-Hwan Kim, Sun Min Lim, Byoung Chul Cho, Mi Ran Yun
• 7036 · PDF EcDNA-mediated oncogene amplification underlies EGFR TKI resistance in NSCLC Boyoon Kim, Sujin Kim, Jeonghee Cho, Hoon Kim
• 7037 · PDF Phospho-reprogramming mitochondrial respiration underlies sunitinib resistance in renal cell carcinoma Gianna Lee Mochi, Samhitha Adavikolanu, Julia K. Burkacki, Mark R. Woodford
• 7038 · PDF SIPA1L3 loss induces TKI resistance via Rap1-MAPK activation in ALK-/RET-fusion positive NSCLC Xinzhao Wei, Jun Adachi, Ryohei Katayama
• 7039 · PDF FER drives drug-tolerant persister cell survival in EGFR-mutant lung cancer Bobak Parang, Rabia Khan, Ariana Kupai, Yuyun Huang, Sungyun Cho, Michal J. Nagiec, Eric E. Gardner, Florencia M. Rowdo, Benjamin D. Hopkins, Qin Fu, Sheng Zheng, Timothy F. Burns, John Blenis
• 7040 · PDF Cancer persister cells are sensitized to copper-mediated death Anna Elizabeth Stuhlfire, August (Gus) Finley Williams, Masayoshi Higuchi, Ariel H. Nguyen, David A. Gervasio, Claire Turkal, Janani Nagasubramanya, Michael Nguyen, Suejean Chon, Matthew Hangauer
• 7041 · PDF Integrated multi-omics and spatial transcriptomics reveal tumor stroma co-evolution driving dabrafenib resistance in BRAF-V600E cholangiocarcinoma Nai-Jung Chiang, Ya-Chin Hou, Chi-Che Hsieh, Chao-Chun Cheng, Che-Hung Shen
• 7042 · PDF Missense mutant p53 regulates DNA replication and damage response to promote resistance to targeted therapies in ALK fusion lung adenocarcinoma Esther Redin, Barbara P. Mello, Yingian A. Zhan, Nicholas Socci, Samuel Tischfield, Alexander Lim, Hong Zhong, Mark Donoghue, Richard Koche, Elisa De Stanchina, Alexander Drilon, Alvaro Quintanal-Villalonga, Charles M. Rudin
• 7044 · PDF Resistance to sorafenib leads to epithelial-to-mesenchymal transition and alterations in cell phenotype in HCC Paulina Marona, Anna Ferenc, Isabel Fabregat, Ester Gonzales Sanchez, Esther Bertran, Javier Vaquero, Jolanta Jura, Katarzyna Miękus
• 7045 · PDF Multi-omics identifies EMT and PI3K/AKT pathways as mechanisms for Astragalus membranaceus polysaccharide-mediated reversal of osimertinib resistance Kenneth K.W. To, Longling Wang, Zhong Zuo, William C. Cho
• 7046 · PDF BRAF/EGFR inhibition induces ERBB2 as a targetable tolerance mechanism in BRAF -mutant colorectal cancer Sara Peltola, Kari J. Kurppa, Klaus Elenius
• 7047 · PDF Characterization of TKI-induced drug-tolerant persister cells from patient-derived cell lines Floriane Braye, Inmaculada Alonso Garcia, Vincent Boursier, Ludovic Bigot, Kristi Beshiri, FRANCESCO FACCHINETTI, Jean-Paul Thiery, Benjamin Besse, Ken A. Olaussen, Luc Friboulet
• 7048 · PDF Neuregulin-1(NRG1 ) -directed therapies induce alkaline phosphatase placental (ALPP) expression in NRG1 -fusion positive cancers: Preclinical data and therapeutic perspective Manon Barre, Clarisse Thiollier-Schmitt, Marie Issenmann, Célia Cortay, Emeline Cros-Perrial, Sandra Ortiz-Cuaran, Nicolas Gadot, Elodie Voilin, Sylvie Lantuejoul, Anthony Ferrari, Eric Cumunel, Charles Dumontet, Lars Petter Jordheim, Michael Duruisseaux
• 7049 · PDF Genome-wide CRISPR-Cas9 screen identifies genes conferring lenvatinib resistance in hepatocellular carcinoma Ayumu Taguchi, Shuang Zhou, Hisanori Isomura, Haruki Mori, Toru Miyake, Yuichi Abe, Miyako Tanaka, Seiji Natsume, Masataka Okuno, Waki Hosoda, Masaji Tani, Takayoshi Suganami
• 7050 7050 A novel 149-amino acid protein encoded by circSOD2 inhibits ferroptosis and promotes cisplatin resistance in bladder cancer Shanqi Guo, Zhihong Lv, Nan Wang, Xingkang Jiang

在会议检索中浏览本分会场